Results 161 to 170 of about 75,053 (306)
“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
Allergy, EarlyView.This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2‐CRSwNP by assessing how many patients maintain disease control with once‐every‐12‐weeks (Q12W) dosing and comparing clinical characteristics of super‐responders and excellent responders. Tapering of dupilumab to Q12W appears feasible in super‐responding patients. P. E. Vonk, J. J. Otten, H. B. E. Elzinga, R. J. L. van der Lans, G. F. J. P. Adriaensen, L. B. L. Benoist, D. R. Hoven, W. J. Fokkens, S. Reitsma, PolyREG Consortium, A.B. Rinia, I. Krebbers, I.J. Kleiss, M. E. Cornet +13 morewiley +1 more sourceProteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U‐BIOPRED Cohort
Allergy, EarlyView.No stable features were identified as associated with asthma symptom control in transcriptomics or sputum proteomics. Higher TWEAKR/TNFRSF12A and MBL/MBP‐C serum levels increased the odds of uncontrolled symptoms, while higher MK08/MAPK8 and CD5L serum levels decreased the odds, after adjustment for clinical variables.Joana Antão, Guilherme Rodrigues, Nazanin Zounemat‐Kermani, Paolo Montuschi, Qichen Deng, Frits M. E. Franssen, Lars I. Andersson, Ian M. Adcock, Sven‐Erik Dahlén, Scott S. Wagers, Martijn A. Spruit, Alda Marques, on behalf of the U‐BIOPRED Study Group, M. I. Abdel‐Aziz, C. Auffray, Y. E. Badi, P. Bakke, A. T. Bansal, F. Baribaud, S. Bates, A. F. Behndig, E. H. Bel, J. Bigler, B. Billing, M. J. Boedigheimer, K. Bønnelykke, J. Brandsma, P. Brinkman, E. Bucchioni, D. Burg, A. Bush, M. Caruso, R. Chalekis, P. Chanez, B. Chaves, F. K. Chung, T. Checa, C. H. Compton, J. Corfield, D. Cunoosamy, A. D’Amico, B. Dahlén, B. De Meulder, R. Djukanovic, V. J. Erpenbeck, D. Erzen, K. Fichtner, L. J. Fleming, E. Formaggio, S. J. Fowler, U. Frey, M. Gahlemann, T. Geiser, V. Goss, Y. Guo, S. Hashimoto, J. Haughney, G. Hedlin, P. W. Hekking, T. Higenbottam, J. M. Hohlfeld, C. Holweg, I. Horváth, P. Howarth, A. J. James, R. G. Knowles, J. Kolmert, J. Konradsen, N. Krug, N. Lazarinis, C.‐X. Li, M. J. Loza, R. Lutter, A. Manta, S. Masefield, Maitland‐van der Zee Anke‐Hilse, J. G. Matthews, A. Mazein, R. J. M. Middelveld, M. Miralpeix, C. S. Murray, J. Musial, S. Mumby, D. Myles, B. Nordlund, H. Olsson, I. Pandis, S. Pavlidis, A. Platt, A. Postle, P. Powel, G. Praticò, M. Puig Valls, N. Rao, S. Reinke, J. Riley, A. Roberts, G. Roberts, A. Rowe, T. Sandström, W. Seibold, D. E. Shaw, R. Sigmund, F. Singer, P. J. Skipp, M. Smicker, A. R. Sousa, M. Sparreman‐Mikus, P. J. Sterk, K. Sun, B. Thornton, A. Versi, N. H. Vissing, A. M. Wheelock, C. E. Wheelock, S. J. Wilson, V. Yasinska, Aliprantis Antonios, Allen David, Alving Kjell, P. Badorrek, Balgoma David, S. Ballereau, Barber Clair, Batuwitage Manohara Kanangana, An Bautmans, A. Bedding, A. F. Behndig, Beleta Jorge, A. Berglind, Bochenek Grazyna, Braun Armin, D. Campagna, Carayannopoulos Leon, C. Casaulta, A. Chaiboonchoe, Davison Timothy, De Alba Jorge, Dekker Tamara, Delin Ingrid, P. Dennison, Dijkhuis Annemiek, Dodson Paul, Draper Aleksandra, K. Dyson, Edwards Jessica, L. El Hadjam, Emma Rosalia, Ericsson Magnus, C. Faulenbach, Flood Breda, G. Galffy, Gallart Hector, D. Garissi, J. Gent, M. Gerhardsson de Verdier, D. Gibeon, Gomez Cristina, Gove Kerry, Gozzard Neil, E. Guillmant‐Farry, E. Henriksson, Hewitt Lorraine, U. Hoda, Hu Richard, Hu Sile, X. Hu, E. Jeyasingham, K. Johnson, N. Jullian, Kamphuis Juliette, J. Kennington Erika, Kerry Dyson, G. Kerry, M. Klüglich, Knobel Hugo, J. Knox Alan, Kolmert Johan, J. R. Konradsen, Kots Maxim, Kretsos Kosmas, L. Krueger, Kuo Scott, Kupczyk Maciej, A.‐S Lantz, Larminie Christopher, L. X. Larsson, P. Latzin, N. Lazarinis, Lefaudeux Diane, N. Lemonnier, Li Chuan‐Xing, Lone‐Latif Saeeda, L. A. Lowe, Manta Alexander, Marouzet Lisa, Martin Jane, Mathon Caroline, L. McEvoy, Meah Sally, A. Menzies‐Gow, Metcalf Leanne, Meiser Andrea, Mikus Maria, Monk Philip, N. Mores, Naz Shama, K. Nething, Nicholas Ben, U. Nihlén, Nilsson Peter, R. Niven, B. Nordlund, S. Nsubuga, Pacino Antonio, Palkonen Susanna, L. Pahus, J. Pellet, Pennazza Giorgio, Petrén Anne, Pink Sandy, C. Pison, Rahman‐Amin Malayka, Ravanetti Lara, Ray Emma, Reinke Stacey, Reynolds Leanne, K. Riemann, Robberechts Martine, J. P. Rocha, C. Rossios, Russell Kirsty, Rutgers Michael, G. Santini, Santonico Marco, M. Saqi, Schoelch Corinna, S. Scott, N. Sehgal, A. Selby, Sjödin Marcus, Smids Barbara, Smith Caroline, Smith Jessica, M. Smith Katherine, P. Söderman, A. Sogbesan, F. Spycher, Staykova Doroteya, S. Stephan, J. Stokholm, K. Strandberg, M. Sunther, M. Szentkereszty, L. Tamasi, K. Tariq, Thörngren John‐Olof, Thorsen Jonathan, S. Valente, W. M. van Aalderen, M. van de Pol, C. M. van Drunen, Van Eyll Jonathan, Versnel Jenny, Vink Anton, C. von Garnier, A. Vyas, A. H. Wagener, Wald Frans, Walker Samantha, Ward Jonathan, Wetzel Kristiane, Wiegman Coen, Z. Weiszhart, Williams Siân, Yang Xian, Yeyasingham Elizabeth, W. Yu, W. Zetterquist, Z. Zolkipli, A. H. Zwinderman, Martina Gahlemann, Luigi Visintin, Hazel Evans, Martine Puhl, Lina Buzermaniene, Val Hudson, Laura Bond, Pim de Boer, Guy Widdershoven, Ralf Sigmund, David Supple, Dominique Hamerlijnck, Jenny Negus, Juliёtte Kamphuis +294 morewiley +1 more sourceSystemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation. [PDF]
Curr Allergy Asthma RepValent P, Hartmann K, Stefanzl G, Filik Y, Bauer K, Degenfeld-Schonburg L, Gleixner KV, Siebenhaar F, Niedoszytko M, Sperr WR, Aghaallaei N, Hoermann G, Sabato V, Orfao A, Arock M, Akin C. +15 moreeuropepmc +1 more sourceElucidating the relationship between affinity and potency in the performance of therapeutic IgE. [PDF]
Sci RepMarano F, McKenzie C, Birtley JR, Hussain SA, Macleod O, Goodacre A, Wu S, Amin OE, Faulkner N, Devlin J, Regan L, Soni K, Johnson RM, Pye VE, Wilson T, Hardaker E, FitzGerald K. +16 moreeuropepmc +1 more sourceLong‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria
Allergy, EarlyView.Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...Ana M. Gimenez‐Arnau, Marcus Maurer, Adam Reich, Chia‐Yu Chu, Diana Deleanu, Gordon Sussman, Jorge Sanchez, Knut Brockow, Koremasa Hayama, Michihiro Hide, Mohamed Denguezli, Raisa Meshkova, Roberta F. J. Criado, Sarbjit Saini, Solange Valle, Eva Hua, Pengpeng Wang, Alis Burciu, Isabelle Indermuehle, Vineeth Varanasi, Yolandi Joubert, Thomas Severin, Manmath Patekar +22 morewiley +1 more source
